FindTrial
Sign In

Improving inpatient GHB detoxification with baclofen: A proof of concept and dose-finding study.

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2023-506167-34-02
Acronym
PaNaMa ID: 114633
Enrollment
28
Registered
2023-12-14
Start date
2025-06-16
Completion date
Unknown
Last updated
2023-12-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

GHB use disorder

Brief summary

The main study parameter is pharmaceutical GHB dosage at the end of the titration phase during inpatient detoxification in patients with GUD

Interventions

DRUGBaclofen Mylan 10 mg
DRUGtabletten
DRUGBaclofen Mylan 25 mg
DRUGXyrem 500 mg/mL oral solution

Sponsors

Stichting Radboud University Medical Center
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to 64 Years

Design outcomes

Primary

MeasureTime frame
The main study parameter is pharmaceutical GHB dosage at the end of the titration phase during inpatient detoxification in patients with GUD—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026